FTB Advisors Inc. Has $235,000 Position in Eli Lilly and Company (LLY)
FTB Advisors Inc. trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 53.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,864 shares of the company’s stock after selling 3,301 shares during the period. FTB Advisors Inc.’s holdings in Eli Lilly and were worth $235,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. Acrospire Investment Management LLC grew its holdings in Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the period. San Francisco Sentry Investment Group CA purchased a new position in Eli Lilly and during the second quarter worth approximately $129,000. Point72 Asia Hong Kong Ltd boosted its position in Eli Lilly and by 237.4% during the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after purchasing an additional 1,239 shares in the last quarter. Shine Investment Advisory Services Inc. purchased a new position in Eli Lilly and during the second quarter worth approximately $148,000. Finally, Cornerstone Advisors Inc. boosted its position in Eli Lilly and by 18.4% during the second quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock worth $166,000 after purchasing an additional 313 shares in the last quarter. 76.61% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Eli Lilly and Company (NYSE LLY) opened at $83.68 on Thursday. Eli Lilly and Company has a fifty-two week low of $64.18 and a fifty-two week high of $89.09. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The company has a market capitalization of $91,919.42, a P/E ratio of 20.41, a P/E/G ratio of 1.84 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter last year, the firm earned $0.88 earnings per share. The business’s revenue for the quarter was up 9.0% on a year-over-year basis. research analysts forecast that Eli Lilly and Company will post 4.21 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a yield of 2.49%. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the sale, the insider now owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the sale, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 772,003 shares of company stock valued at $64,837,441. 0.20% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: This story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/11/23/ftb-advisors-inc-has-235000-position-in-eli-lilly-and-company-lly.html.
A number of equities analysts have issued reports on the company. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, October 24th. Barclays PLC increased their price target on Eli Lilly and from $90.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, October 13th. Berenberg Bank reiterated a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a research report on Thursday, October 26th. Zacks Investment Research downgraded Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Cowen and Company reiterated a “buy” rating and set a $95.00 price target on shares of Eli Lilly and in a research report on Wednesday, October 4th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $89.97.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.